Inflexion

Inflexion is a mid-market private equity firm with U.S. presence in Boston and a strong UK and European heritage, partnering with ambitious healthcare and technology founders to accelerate international growth. Within healthcare, the firm focuses on Health IT/Healthcare Software, which makes it more software-comfortable than the average growth-stage PE sponsor. AI is not a dedicated thesis. Specific AUM information is not detailed in the source data.

Check sizes are $25M+ at the growth stage, with both minority growth and partnership-style buyouts in the firm’s repertoire. Inflexion’s heritage means it brings particular value for U.S. companies seeking to scale into Europe. Specific portfolio companies are not listed in the source data. Diligence emphasizes growth durability, international expansion potential, and management appetite for cross-border execution.

Founders should consider Inflexion once their health IT business has crossed roughly $15-20M+ in ARR and has a credible thesis for international expansion. The wrong investor at seed or Series A. The right profile is a CEO running a scaled vertical SaaS or healthcare software platform that wants a partner with hands-on cross-Atlantic experience to support the next phase of growth.